UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 156

Sortiert nach

Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study

Cancer, 2017-04, Vol.123 (8), p.1464-1474

2017

Volltextzugriff (PDF)

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403

Journal of clinical oncology, 2020-12, Vol.38 (34), p.4076-4085

2020

Volltextzugriff (PDF)

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Journal of thoracic oncology, 2018-12, Vol.13 (12), p.1818-1831

2018

Volltextzugriff (PDF)

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

Clinical cancer research, 2015-04, Vol.21 (7), p.1514-1524

2015

Volltextzugriff (PDF)

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2530-2535

2009

Volltextzugriff (PDF)

Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)

JNCI : Journal of the National Cancer Institute, 2018-07, Vol.110 (7), p.734-742

2018

Volltextzugriff (PDF)

Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

Journal of clinical oncology, 2008-01, Vol.26 (3), p.463-467

2008

Volltextzugriff (PDF)

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

Clinical lung cancer, 2014-01, Vol.15 (1), p.1-6

2014

Volltextzugriff (PDF)

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Journal for immunotherapy of cancer, 2021-08, Vol.9 (8), p.e002973

2021

Volltextzugriff (PDF)

Health-Related Quality of Life Results in Pathologic Stage C Prostate Cancer From a Southwest Oncology Group Trial Comparing Radical Prostatectomy Alone With Radical Prostatectomy Plus Radiation Therapy

Journal of clinical oncology, 2008-01, Vol.26 (1), p.112-120

2008

Volltextzugriff (PDF)

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

Journal of thoracic oncology, 2015-07, Vol.10 (7), p.1099-1106

2015

Volltextzugriff (PDF)

Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non–Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003

Journal of clinical oncology, 2008-10, Vol.26 (29), p.4771-4776

2008

Volltextzugriff (PDF)

The Master Protocol Concept

Seminars in oncology, 2015-10, Vol.42 (5), p.724-730

2015

Volltextzugriff (PDF)

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A

Journal of clinical oncology, 2022-07, Vol.40 (21), p.2295-2307

2022

Volltextzugriff (PDF)

Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience

Head & neck, 2016-09, Vol.38 (9), p.1318-1323

2016

Volltextzugriff (PDF)

Moving Toward Rationale Phase 3 Designs for Advanced NSCLC

Journal of thoracic oncology, 2023-12, Vol.18 (12), p.1629-1631

2023

Volltextzugriff (PDF)

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)

Clinical cancer research, 2022-09, Vol.28 (17), p.3752-3760

2022

Volltextzugriff (PDF)

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.1847-1852

2019

Volltextzugriff (PDF)

Racial disparities in the screening mammography continuum within a heterogeneous health care system

Cancer, 2023-09, Vol.129 (S19), p.3171-3181

2023

Volltextzugriff (PDF)

SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.1853-1859

2019

Volltextzugriff (PDF)

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial

JAMA oncology, 2020-11, Vol.6 (11), p.1778

2020

Volltextzugriff (PDF)

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

Journal of clinical oncology, 2019-10, Vol.37 (28), p.2537-2547

2019

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(149)
Mit Volltextzugriff
(126)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(156)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Science & Technology
(106)
Humans
(103)
Life Sciences & Biomedicine
(101)
Oncology
(67)
Female
(60)
Male
(54)
Middle Aged
(41)
Aged
(37)
Lung Neoplasms - Drug Therapy
(33)
Adult
(32)
Aged, 80 And Over
(26)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(24)
Biological And Medical Sciences
(23)
Lung Neoplasms - Pathology
(23)
Medical Sciences
(23)
Neoplasm Staging
(18)
Treatment Outcome
(18)
Pregnancy
(16)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(15)
Carcinoma, Non-Small-Cell Lung - Pathology
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)

Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

Health-Related Quality of Life Results in Pathologic Stage C Prostate Cancer From a Southwest Oncology Group Trial Comparing Radical Prostatectomy Alone With Radical Prostatectomy Plus Radiation Therapy

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non–Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003

The Master Protocol Concept

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A

Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience

Moving Toward Rationale Phase 3 Designs for Advanced NSCLC

T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

Racial disparities in the screening mammography continuum within a heterogeneous health care system

Scientific Advances in Lung Cancer 2015

SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

Suchergebnisse filtern